

## 식도영역 자료추출 및 비뚤림위험

<b>연번(Ref ID)</b>	1(5059)																													
<b>1저자(출판연도)</b>	de Groot(2020) (ROBOT trial)																													
<b>연구특성</b>	<ul style="list-style-type: none"> <li>연구수행국: 네덜란드</li> <li>연구설계: RCT</li> <li>연구기관: 단일기관 연구 ROBOT trial</li> <li>연구수행기간: 2012년 4월~2016년 8월</li> <li>ROBOT trial NCT01544790;</li> <li>질환명(세부내용) <ul style="list-style-type: none"> <li>surgically resectable (cT1-4a, N0-3, M0) cancer of the intrathoracic esophagus</li> </ul> </li> </ul>																													
<b>연구대상</b>	<ul style="list-style-type: none"> <li>선택기준 <ul style="list-style-type: none"> <li>18세 이상 80세 이하의 성인</li> <li>식도암 적출가능 환자</li> </ul> </li> <li>환자수 : 109명(중재군=54, 대조군=55명)</li> </ul>																													
<b>중재법</b>	<ul style="list-style-type: none"> <li>중재명: robot-assisted minimally invasive esophagectomy (RAMIE)</li> </ul>																													
<b>비교중재법 (비교중재법이 없으면 생략)</b>	<ul style="list-style-type: none"> <li>중재명: open transthoracic esophagectomy (OTE)</li> </ul>																													
<b>추적관찰 및 결과변수</b>	<ul style="list-style-type: none"> <li>추적관찰기간: 30일, 60일, 90일</li> </ul>																													
<b>연구결과-안전성</b>	<table border="1"> <thead> <tr> <th rowspan="2">변수</th> <th colspan="3">RAMIE</th> <th colspan="3">OTE</th> <th rowspan="2">군간 P-value</th> </tr> <tr> <th>N</th> <th>n</th> <th>%</th> <th>N</th> <th>n</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>재발</td> <td>50</td> <td>28</td> <td>56</td> <td>54</td> <td>29</td> <td>54</td> <td>0.814</td> </tr> </tbody> </table>								변수	RAMIE			OTE			군간 P-value	N	n	%	N	n	%	재발	50	28	56	54	29	54	0.814
변수	RAMIE			OTE			군간 P-value																							
	N	n	%	N	n	%																								
재발	50	28	56	54	29	54	0.814																							
<b>연구결과-유효성</b>	<ul style="list-style-type: none"> <li>결과 <table border="1"> <thead> <tr> <th rowspan="2">변수</th> <th colspan="2">RAMIE</th> <th colspan="2">OTE</th> <th rowspan="2">군간 P-value</th> </tr> <tr> <th>n</th> <th>%(95%CI)</th> <th>n</th> <th>%(95%CI)</th> </tr> </thead> <tbody> <tr> <td>median overall survival 5년시점</td> <td>54</td> <td>42(27-55)</td> <td>55</td> <td>40(26-53)</td> <td>0.827</td> </tr> <tr> <td>disease-free survival rates rate 5년시점</td> <td>54</td> <td>42(28-55)</td> <td>55</td> <td>43(29-57)</td> <td>0.749</td> </tr> </tbody> </table> </li> </ul>								변수	RAMIE		OTE		군간 P-value	n	%(95%CI)	n	%(95%CI)	median overall survival 5년시점	54	42(27-55)	55	40(26-53)	0.827	disease-free survival rates rate 5년시점	54	42(28-55)	55	43(29-57)	0.749
변수	RAMIE		OTE		군간 P-value																									
	n	%(95%CI)	n	%(95%CI)																										
median overall survival 5년시점	54	42(27-55)	55	40(26-53)	0.827																									
disease-free survival rates rate 5년시점	54	42(28-55)	55	43(29-57)	0.749																									
<b>결론</b>	로봇 보조수술은 식도암 환자에서 식도절제술을 시행하기 위해 개흉수술보다 더 선호된다.																													
<b>funding</b>																														
<b>비고</b>																														

\* 제 1저자 기준

## 자료추출 양식(안)\_중재평가

연번(Ref ID)	2(9011)																																																																																																						
1저자(출판연도)	van der Sluis(2019) (ROBOT trial)																																																																																																						
연구특성	<ul style="list-style-type: none"> <li>연구수행국: 네덜란드</li> <li>연구설계: RCT</li> <li>연구기관: 단일기관 연구 ROBOT trial</li> <li>연구수행기간: 2012년 4월~2016년 8월</li> <li>ROBOT trial NCT01544790;</li> <li>질환명(세부내용) <ul style="list-style-type: none"> <li>- surgically resectable (cT1-4a, N0-3, M0) cancer of the intrathoracic esophagus</li> </ul> </li> </ul>																																																																																																						
연구대상	<ul style="list-style-type: none"> <li>선택기준 <ul style="list-style-type: none"> <li>- 18세 이상 80세 이하의 성인</li> <li>- 식도암 적출가능 환자</li> </ul> </li> <li>환자수 : 109명(중재군=54, 대조군=55명)</li> </ul>																																																																																																						
중재법	<ul style="list-style-type: none"> <li>중재명: robot-assisted minimally invasive esophagectomy (RAMIE)</li> </ul>																																																																																																						
비교중재법 (비교중재법이 없으면 생략)	<ul style="list-style-type: none"> <li>중재명: open transthoracic esophagectomy (OTE)</li> </ul>																																																																																																						
추적관찰 및 결과변수	<ul style="list-style-type: none"> <li>추적관찰기간: 30일, 60일, 90일</li> <li>결과 <ul style="list-style-type: none"> <li>- 사망: RAMIE 2명의 환자가 문합 누출 후 종격염 OTE 1명 기관 식도 누공</li> </ul> </li> </ul>																																																																																																						
연구결과-안전성	<table border="1"> <thead> <tr> <th rowspan="2">변수</th> <th colspan="3">RAMIE</th> <th colspan="3">OTE</th> <th rowspan="2">군간 P-value</th> </tr> <tr> <th>N</th> <th>n</th> <th>%</th> <th>N</th> <th>n</th> <th>%</th> </tr> </thead> <tbody> <tr> <td>Primary endpoint</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Related complications (MCDC 2, 3, 4, and 5) Å</td> <td>54</td> <td>32</td> <td>59</td> <td>55</td> <td>44</td> <td>80</td> <td>0.02</td> </tr> <tr> <td>Pulmonary complications</td> <td>54</td> <td>17</td> <td>32</td> <td>55</td> <td>32</td> <td>58</td> <td>0.005</td> </tr> <tr> <td>Cardiac complications</td> <td>54</td> <td>12</td> <td>22</td> <td>55</td> <td>26</td> <td>47</td> <td>0.006</td> </tr> <tr> <td>Wound infections</td> <td>54</td> <td>2</td> <td>4</td> <td>55</td> <td>8</td> <td>10</td> <td>0.09</td> </tr> <tr> <td>Anastomotic leakage</td> <td>54</td> <td>13</td> <td>24</td> <td>55</td> <td>11</td> <td>20</td> <td></td> </tr> <tr> <td>Mediastinitis, 종격동염</td> <td>54</td> <td>12</td> <td>22</td> <td>55</td> <td>11</td> <td>20</td> <td>0.42</td> </tr> <tr> <td>Thoracic empyema, 농흉</td> <td>54</td> <td>2</td> <td>4</td> <td>55</td> <td>3</td> <td>6</td> <td>1.00</td> </tr> <tr> <td>Gastric conduit necrosis</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> </tr> <tr> <td>Type III (conduit necrosis extensive, treated with resection and diversion)</td> <td>54</td> <td>1</td> <td>2</td> <td>55</td> <td>2</td> <td>4</td> <td>0.69</td> </tr> <tr> <td>Chylothorax, 유미흉</td> <td>54</td> <td>17</td> <td>32</td> <td>55</td> <td>12</td> <td>22</td> <td></td> </tr> </tbody> </table>	변수	RAMIE			OTE			군간 P-value	N	n	%	N	n	%	Primary endpoint								Related complications (MCDC 2, 3, 4, and 5) Å	54	32	59	55	44	80	0.02	Pulmonary complications	54	17	32	55	32	58	0.005	Cardiac complications	54	12	22	55	26	47	0.006	Wound infections	54	2	4	55	8	10	0.09	Anastomotic leakage	54	13	24	55	11	20		Mediastinitis, 종격동염	54	12	22	55	11	20	0.42	Thoracic empyema, 농흉	54	2	4	55	3	6	1.00	Gastric conduit necrosis								Type III (conduit necrosis extensive, treated with resection and diversion)	54	1	2	55	2	4	0.69	Chylothorax, 유미흉	54	17	32	55	12	22	
변수	RAMIE			OTE			군간 P-value																																																																																																
	N	n	%	N	n	%																																																																																																	
Primary endpoint																																																																																																							
Related complications (MCDC 2, 3, 4, and 5) Å	54	32	59	55	44	80	0.02																																																																																																
Pulmonary complications	54	17	32	55	32	58	0.005																																																																																																
Cardiac complications	54	12	22	55	26	47	0.006																																																																																																
Wound infections	54	2	4	55	8	10	0.09																																																																																																
Anastomotic leakage	54	13	24	55	11	20																																																																																																	
Mediastinitis, 종격동염	54	12	22	55	11	20	0.42																																																																																																
Thoracic empyema, 농흉	54	2	4	55	3	6	1.00																																																																																																
Gastric conduit necrosis																																																																																																							
Type III (conduit necrosis extensive, treated with resection and diversion)	54	1	2	55	2	4	0.69																																																																																																
Chylothorax, 유미흉	54	17	32	55	12	22																																																																																																	

연번(Ref ID)	2(9011)						
1저자(출판연도)	van der Sluis(2019) (ROBOT trial)						
Postoperative bleeding	54	2	4	55	2	4	1.00
Readmission intensive care unit, 재입원	54	10	19	55	7	13	0.41
Hospital readmission within 30 days [n (%)]	54	6	12	55	4	7	0.52
Reoperations, 재수술	54	13	24	55	18	33	0.32
In-hospital mortality	54	2	4	55	1	2	0.62
30-Day mortality	54	1	2	55	0	0	0.50
60-Day mortality	54	3	6	55	1	2	0.36
90-Day mortality	54	5	9	55	1	2	0.11
Additional PCA after removal of epidural [n (%)]	54	1	2	55	5	9	0.11
Conversion [n (%)]	54	3	5	55	NA		
Intraoperative complications [n (%)]	54	17	13	55	9	16	0.62

• 결과

연구결과-유효성

변수	RAMIE			OTE			군간 P-value
	N	n	%	N	n	%	
Hospital stay (days—IQ range)	54	14	(11-25)	55	16	(11-27)	0.33
Functional recovery within first 2 weeks [n (%)]	54	38	70	55	28	51	0.04
Quality of life (QLQ-C30)							
Health-related quality of life (discharge)	31	57.9	(49.9-66.1)	33	44.6	(36.7-52.5)	0.02
Health-related quality of life (6 wk) <b>95% CI.</b>	31	68.7	(61.5-75.9)	33	57.6	(50.6-64.6)	0.03
Physical functioning (discharge)	31	54.5	(45.8-63.3)	33	41.0	(32.4-49.6)	0.03
Physical functioning (6 wk)	31	69.3	(61.6-76.9)	33	58.6	(51.1-66.0)	0.049
수술후 통증 VAS	54	1.86		55	2.62		<0.001
	N	mean	SD	N	mean	SD	
Total Operating time (분)	54	349	56.9	55	296	33.9	<0.001
Total blood loss, mL—IQ range	54	400	258-581	55	568	428-800	<0.001
Lymph nodes number (number—IQ range)	54	27	(17-33)	55	25	(17-31)	0.41



<b>연번(Ref ID)</b>	<b>3</b>																																																																																								
<b>1저자(출판연도)</b>	<b>Yang(2022)</b>																																																																																								
<b>연구대상</b>	<ul style="list-style-type: none"> <li>• NCT03094351</li> <li>• 질환명(세부내용) <ul style="list-style-type: none"> <li>- 식도암(esophageal squamous cell carcinoma (ESCC))</li> </ul> </li> <li>• 선택기준 <ul style="list-style-type: none"> <li>- 18 ~ 75세</li> <li>- European Clinical Oncology Group performance status of 0, 1, or 2, with primarily resectable ESCC [cT1-4a, N0-2, and M0 or M1 (lymph node metastasis confined to the supraclavicular lymph nodes), 7th edition of the American Joint Committee for Cancer staging manual 15 ] of the intrathoracic esophagus</li> </ul> </li> <li>• 환자수 : 181/177</li> <li>• 연령(median (range)): 65 (43-75)/63 (42-75)</li> </ul>																																																																																								
<b>중재법</b>	<ul style="list-style-type: none"> <li>• 중재명: robotassisted minimally invasive esophagectomy (RAMIE)</li> </ul>																																																																																								
<b>비교중재법 (비교중재법이 없으면 생략)</b>	<ul style="list-style-type: none"> <li>• 중재명: Thoracoscopic esophagectomy(minimally invasive esophagectomy (MIE))</li> </ul>																																																																																								
<b>추적관찰 및 결과변수</b>	<ul style="list-style-type: none"> <li>• 추적관찰기간: 매 3개월, 1년까지</li> </ul>																																																																																								
<b>결과분석방법</b>	<ul style="list-style-type: none"> <li>• 결과변수:</li> <li>• 통계방법:</li> </ul>																																																																																								
<b>연구결과-안전성</b>	<table border="1"> <thead> <tr> <th rowspan="2">변수</th> <th colspan="2">RAMIE(181)</th> <th colspan="2">MIE (177)</th> <th rowspan="2">P value</th> </tr> <tr> <th>N</th> <th>%</th> <th>N</th> <th>%</th> </tr> </thead> <tbody> <tr> <td><b>Total complications</b></td> <td>88</td> <td>48.6</td> <td>74</td> <td>41.8</td> <td>0.196</td> </tr> <tr> <td>  C-D classification ≥ III</td> <td>12</td> <td>12.2</td> <td>18</td> <td>10.2</td> <td>0.551</td> </tr> <tr> <td><b>Pulmonary complications</b></td> <td>25</td> <td>13.8</td> <td>26</td> <td>14.7</td> <td>0.812</td> </tr> <tr> <td>  Pneumonia</td> <td>18</td> <td>9.9</td> <td>21</td> <td>11.9</td> <td>0.560</td> </tr> <tr> <td>  Respiratory failure</td> <td>8</td> <td>4.4</td> <td>9</td> <td>5.1</td> <td>0.767</td> </tr> <tr> <td>  Pleural effusion</td> <td>10</td> <td>5.5</td> <td>6</td> <td>3.4</td> <td>0.328</td> </tr> <tr> <td>  Pneumothorax</td> <td>3</td> <td>1.7</td> <td>5</td> <td>2.8</td> <td>0.499</td> </tr> <tr> <td><b>Severe cardiac complications</b></td> <td>2</td> <td>1.1</td> <td>1</td> <td>0.6</td> <td>0.631</td> </tr> <tr> <td><b>Anastomotic leakage</b></td> <td>22</td> <td>12.2</td> <td>20</td> <td>11.3</td> <td>0.801</td> </tr> <tr> <td>  Type I (conservative)</td> <td>8</td> <td>4.4</td> <td>5</td> <td>2.8</td> <td></td> </tr> <tr> <td>  Type II (nonsurgical intervention)</td> <td>13</td> <td>7.2</td> <td>14</td> <td>7.9</td> <td></td> </tr> <tr> <td>  Type III (surgical intervention)</td> <td>1</td> <td>0.6</td> <td>1</td> <td>0.6</td> <td></td> </tr> <tr> <td><b>Vocal cord paralysis</b></td> <td>59</td> <td>32.6</td> <td>48</td> <td>27.1</td> <td>0.258</td> </tr> </tbody> </table>	변수	RAMIE(181)		MIE (177)		P value	N	%	N	%	<b>Total complications</b>	88	48.6	74	41.8	0.196	C-D classification ≥ III	12	12.2	18	10.2	0.551	<b>Pulmonary complications</b>	25	13.8	26	14.7	0.812	Pneumonia	18	9.9	21	11.9	0.560	Respiratory failure	8	4.4	9	5.1	0.767	Pleural effusion	10	5.5	6	3.4	0.328	Pneumothorax	3	1.7	5	2.8	0.499	<b>Severe cardiac complications</b>	2	1.1	1	0.6	0.631	<b>Anastomotic leakage</b>	22	12.2	20	11.3	0.801	Type I (conservative)	8	4.4	5	2.8		Type II (nonsurgical intervention)	13	7.2	14	7.9		Type III (surgical intervention)	1	0.6	1	0.6		<b>Vocal cord paralysis</b>	59	32.6	48	27.1	0.258
변수	RAMIE(181)		MIE (177)		P value																																																																																				
	N	%	N	%																																																																																					
<b>Total complications</b>	88	48.6	74	41.8	0.196																																																																																				
C-D classification ≥ III	12	12.2	18	10.2	0.551																																																																																				
<b>Pulmonary complications</b>	25	13.8	26	14.7	0.812																																																																																				
Pneumonia	18	9.9	21	11.9	0.560																																																																																				
Respiratory failure	8	4.4	9	5.1	0.767																																																																																				
Pleural effusion	10	5.5	6	3.4	0.328																																																																																				
Pneumothorax	3	1.7	5	2.8	0.499																																																																																				
<b>Severe cardiac complications</b>	2	1.1	1	0.6	0.631																																																																																				
<b>Anastomotic leakage</b>	22	12.2	20	11.3	0.801																																																																																				
Type I (conservative)	8	4.4	5	2.8																																																																																					
Type II (nonsurgical intervention)	13	7.2	14	7.9																																																																																					
Type III (surgical intervention)	1	0.6	1	0.6																																																																																					
<b>Vocal cord paralysis</b>	59	32.6	48	27.1	0.258																																																																																				

연번(Ref ID)	3					
1저자(출판연도)	Yang(2022)					
Type I (transient injury requiring no therapy)	55	30.4	45	25.4		
Type II (requiring elective surgical procedure)	1	0.6	1	0.6		
Type III (requiring acute surgical intervention)	3	1.7	2	1.1		
Location (Left/right/bilateral)	49 (27.1)/6 (3.3)/4 (2.2)		41 (23.2)/4 (2.3)/3 (1.7)		0.573	
<b>Chylothoraxy</b>	5	2.8	2	1.1	0.449	
Type I (enteric dietary modifications)	4	2.2	1	0.6		
Type II (total parenteral nutrition)	1	0.6	1	0.6		
Type III (interventional or surgical therapy)	0	0	0	0		
<b>Wound infections</b>	3	1.7	1	0.6	0.623	
Intensive care unit stay (d), median (range)	1	0-15	1	0-14	0.990	
<b>Readmission intensive care unit</b>	3	1.7	3	1.7	0.815	
Conversion	7	3.9	6	(3.4)	0.926	

• 결과

연구결과-유효성

변수	RAMIE(181)		MIE (177)		P value
	mean	SD	mean	SD	
Total operation time	203.8	59.4	244.9	61.0	<0.001
Blood loss [median (IQR)]	200	(100-400)	200	(100-500)	0.382
Total Number of LNs[median (IQR)]	23	16-33	23	14-30	0.636
Postoperative hospital stay (d), median (range)	9	6-49	9	6-82	0.311
	n	%	n	%	
<b>In-hospital mortality*</b>	0	0	0	0	
<b>30-d mortality*</b>	0	0	1	0.6	0.633
<b>90-d mortality*</b>	1	0.6	1	0.6	0.909

\*생존율로 변경하여 활용

결론

초기 결과는 RAMIE와 MIE가 모두 식도암 수술에 안전하고 실현 가능하다고 보고함. RAMIE는 새로운 보조치료를 받는 환자에서 더 짧은 수술 기간과 더 나은 림프절 절제를 할수 있다는 것을 보고함.

funding

비고

\* 제 1저자 기준

비뚤림 위험 평가		
Risk of Bias (RCT인 경우만)		
영역	비뚤림 위험	판단근거(논문인용)
무작위 배정순서 생성	<input type="checkbox"/> 높음 <input checked="" type="checkbox"/> 낮음 <input type="checkbox"/> 불확실	<ul style="list-style-type: none"> <li>concealment of allocation was performed using computergenerated random numbers</li> </ul>
배정순서 은폐	<input type="checkbox"/> 높음 <input checked="" type="checkbox"/> 낮음 <input type="checkbox"/> 불확실	<ul style="list-style-type: none"> <li>concealment of allocation was performed using computergenerated random numbers</li> </ul>
참여자, 연구자 눈가림 여부	<input checked="" type="checkbox"/> 높음 <input type="checkbox"/> 낮음 <input type="checkbox"/> 불확실	<ul style="list-style-type: none"> <li>There was no blinding for the patient and operator due to practical difficulties.</li> </ul>
결과 평가자 눈가림 여부	<input type="checkbox"/> 높음 <input checked="" type="checkbox"/> 낮음 <input type="checkbox"/> 불확실	<ul style="list-style-type: none"> <li>All outcomes were recorded and prospectively reviewed by the central study coordinator of the trial</li> </ul>
불완전한 결과자료	<input type="checkbox"/> 높음 <input checked="" type="checkbox"/> 낮음 <input type="checkbox"/> 불확실	<ul style="list-style-type: none"> <li>사전 중재군 대조군 환자수가 각각 183명, 179명에서 사후 181명, 177명으로 결측치가 결과에 영향을 미치지 않음</li> <li>The demographic and clinical characteristics of the 2 groups did not differ significantly at baseline</li> </ul>
선택적 결과보고	<input type="checkbox"/> 높음 <input checked="" type="checkbox"/> 낮음 <input type="checkbox"/> 불확실	<ul style="list-style-type: none"> <li>프로토콜이 존재하지 않지만 연구방법에서 사전에 정의해놓은 결과들이 연구결과에서 모두 제시되고 있음</li> </ul>
기타 비뚤림 위험 (민간연구비 지원)	<input type="checkbox"/> 높음 <input checked="" type="checkbox"/> 낮음 <input type="checkbox"/> 불확실	<ul style="list-style-type: none"> <li>의료기기 업체의 지원을 받지 않음</li> <li>This study was funded by the Shanghai Hospital Development Center</li> </ul>